Licensing Terms and Agreements in Pharma, Biotech and Diagnostics
Published: Aug 2014 | Publisher: Current Partnering | Pages: 1195SUMMARY
The Licensing Terms and Agreements in Pharma, Biotech and Diagnostics report provides comprehensive understanding and unprecedented access to the licensing deals and agreements entered into by the worlds leading life science companies
TABLE OF CONTENTS
Executive Summary
Chapter 1 – Introduction
Chapter 2 – Trends in licensing dealmaking
2.1. Introduction
2.2. Definition of licensing deals
2.3. Success factors for licensing deals
2.4. When licensing can be useful
2.5. Attributes of licensing deals
2.6. Trends in licensing deals since 2009
2.7. Option to license
2.8. Adding co-promotion to the mix
2.9. The future of licensing deals
Chapter 3 – Overview of licensing deal structure
3.1. Introduction
3.2. Pure versus multi-component licensing deals
3.3. Pure licensing agreement structure
3.3.1. Example licensing agreements
3.3.1.a. Case study 1: Ignyta – Nerviano Medical Sciences – November 2013
3.3.1.b. Case study 2: Sanofi - Pozen – September 2013
3.4. Licensing rights as part of a wider alliance agreement
3.4.1. Example licensing clauses
3.4.1.a. Case study 3: 4D Molecular Therapeutics – UniQure – January 2014
3.4.1.b. Case study 4: Kyowa Hakko Kirin – Ultragenyx Pharmaceuticals – September 2013
3.4.2. Example licensing option right clauses
3.4.2.a. Case study 5: Forest Laboratories - Trevena – May 2013
3.4.2.b. Case study 6: Abbvie – Receptos – March 2013
Chapter 4 – Leading licensing deals
4.1. Introduction
4.2. Top licensing deals by value
4.3. Most active licensing dealmakers
4.3.1 Most active licensing dealmakers by therapy
4.3.2. Most active licensing dealmaker by stage of development
4.4. Bigpharma licensing deal activity
4.4. Bigbiotech licensing deal activity
Chapter 5 – Licensing deal term benchmarks
5.1. Introduction
5.2.1. Licensing headline values
5.2.2. Licensing upfront payments
5.2.3. Licensing milestone payments
5.2.4. Licensing royalty rates
Chapter 6 – Bigpharma licensing deals
6.1. Introduction
6.2. How to use licensing deals
6.3. Company licensing agreement listings
Chapter 7 – Bigbiotech licensing deals
7.1. Introduction
7.2. How to use licensing deals
7.3. Company licensing agreement listings
Chapter 8 – Licensing contract directory 2009-2014
8.1. Introduction
8.2. Company A-Z
Appendices
Appendix 1 – Licensing dealmaking - by financial disclosure
Appendix 2 – Licensing dealmaking - by companies A-Z
Appendix 3 – Licensing dealmaking - by stage of development
Appendix 4 – Licensing dealmaking - by therapeutic target
Appendix 5 – Licensing dealmaking - by technology type
Table of figures
Figure 1: Definition of licensing
Figure 2: Situations where licensing can prove useful
Figure 3: Key attributes of a licensing deal
Figure 4: Trends in licensing deal announcements, 2009-2014
Figure 5: Licensing deals signed at each phase of development, 2009-2014
Figure 6: Licensing deals by therapy area, 2009-2014
Figure 7: Licensing agreements – what should a contract include?
Figure 8: Components of the licensing deal structure
Figure 9: Top licensing deals by value since 2009 exceeding $1bn
Figure 10: Most active licensing dealmakers 2009-2014
Figure 11: Most active licensing dealmakers 2009-2014 by therapy area
Figure 12: Most active licensing dealmakers 2009-2014 – by stage of development
Figure 13: Bigpharma – top 50 – licensing deals 2009 to 2014
Figure 14: Bigpharma licensing deal frequency - 2009 to 2014
Figure 15: Bigbiotech – top 50 – licensing deals 2009 to 2014
Figure 16: Bigbiotech licensing deal frequency - 2009 to 2014
Figure 17: Licensing deal headline value distribution, US$million – discovery stage
Figure 18: Licensing deal headline value distribution, US$million – preclinical stage
Figure 19: Licensing deal headline value distribution, US$million – phase I stage
Figure 20: Licensing deal headline value distribution, US$million – phase II stage
Figure 21: Licensing deal headline value distribution, US$million – phase III stage
Figure 22: Licensing deal headline value distribution, US$million – regulatory stage
Figure 23: Licensing deal headline value distribution, US$million – marketed stage
Figure 24: Summary median licensing headline value by stage of development, 2009-2014
Figure 25: Licensing deal upfront payment distribution, US$million – discovery stage
Figure 26: Licensing deal upfront payment distribution, US$million – preclinical stage
Figure 27: Licensing deal upfront payment distribution, US$million – phase I stage
Figure 28: Licensing deal upfront payment distribution, US$million – phase II stage
Figure 29: Licensing deal upfront payment distribution, US$million – phase III stage
Figure 30: Licensing deal upfront payment distribution, US$million – regulatory stage
Figure 31: Licensing deal upfront payment distribution, US$million – marketed stage
Figure 32: Summary median licensing upfront payments by stage of development, 2009-2014
Figure 33: Licensing deal milestone distribution, US$million – discovery stage
Figure 34: Licensing deal milestone distribution, US$million – preclinical stage
Figure 35: Licensing deal milestone distribution, US$million – phase I stage
Figure 36: Licensing deal milestone distribution, US$million – phase II stage
Figure 37: Licensing deal milestone distribution, US$million – phase III stage
Figure 38: Licensing deal milestone distribution, US$million – regulatory stage
Figure 39: Licensing deal milestone distribution, US$million – marketed stage
Figure 40: Licensing deals with royalty rates, %
Figure 41: Licensing deal royalty rate distribution, US$million – discovery stage
Figure 42: Licensing deal royalty rate distribution, US$million – preclinical stage
Figure 43: Licensing deal royalty rate distribution, US$million – phase I stage
Figure 44: Licensing deal royalty rate distribution, US$million – phase II stage
Figure 45: Licensing deal royalty rate distribution, US$million – phase III stage
Figure 46: Licensing deal royalty rate distribution, US$million – regulatory stage
Figure 47: Licensing deal royalty rate distribution, US$million – marketed stage
Figure 48: Summary median licensing royalty rate by stage of development, 2009-2014
Figure 49: Online partnering resources
Figure 50: Deal type definitions
Chapter 1 – Introduction
Chapter 2 – Trends in licensing dealmaking
2.1. Introduction
2.2. Definition of licensing deals
2.3. Success factors for licensing deals
2.4. When licensing can be useful
2.5. Attributes of licensing deals
2.6. Trends in licensing deals since 2009
2.7. Option to license
2.8. Adding co-promotion to the mix
2.9. The future of licensing deals
Chapter 3 – Overview of licensing deal structure
3.1. Introduction
3.2. Pure versus multi-component licensing deals
3.3. Pure licensing agreement structure
3.3.1. Example licensing agreements
3.3.1.a. Case study 1: Ignyta – Nerviano Medical Sciences – November 2013
3.3.1.b. Case study 2: Sanofi - Pozen – September 2013
3.4. Licensing rights as part of a wider alliance agreement
3.4.1. Example licensing clauses
3.4.1.a. Case study 3: 4D Molecular Therapeutics – UniQure – January 2014
3.4.1.b. Case study 4: Kyowa Hakko Kirin – Ultragenyx Pharmaceuticals – September 2013
3.4.2. Example licensing option right clauses
3.4.2.a. Case study 5: Forest Laboratories - Trevena – May 2013
3.4.2.b. Case study 6: Abbvie – Receptos – March 2013
Chapter 4 – Leading licensing deals
4.1. Introduction
4.2. Top licensing deals by value
4.3. Most active licensing dealmakers
4.3.1 Most active licensing dealmakers by therapy
4.3.2. Most active licensing dealmaker by stage of development
4.4. Bigpharma licensing deal activity
4.4. Bigbiotech licensing deal activity
Chapter 5 – Licensing deal term benchmarks
5.1. Introduction
5.2.1. Licensing headline values
5.2.2. Licensing upfront payments
5.2.3. Licensing milestone payments
5.2.4. Licensing royalty rates
Chapter 6 – Bigpharma licensing deals
6.1. Introduction
6.2. How to use licensing deals
6.3. Company licensing agreement listings
Chapter 7 – Bigbiotech licensing deals
7.1. Introduction
7.2. How to use licensing deals
7.3. Company licensing agreement listings
Chapter 8 – Licensing contract directory 2009-2014
8.1. Introduction
8.2. Company A-Z
Appendices
Appendix 1 – Licensing dealmaking - by financial disclosure
Appendix 2 – Licensing dealmaking - by companies A-Z
Appendix 3 – Licensing dealmaking - by stage of development
Appendix 4 – Licensing dealmaking - by therapeutic target
Appendix 5 – Licensing dealmaking - by technology type
Table of figures
Figure 1: Definition of licensing
Figure 2: Situations where licensing can prove useful
Figure 3: Key attributes of a licensing deal
Figure 4: Trends in licensing deal announcements, 2009-2014
Figure 5: Licensing deals signed at each phase of development, 2009-2014
Figure 6: Licensing deals by therapy area, 2009-2014
Figure 7: Licensing agreements – what should a contract include?
Figure 8: Components of the licensing deal structure
Figure 9: Top licensing deals by value since 2009 exceeding $1bn
Figure 10: Most active licensing dealmakers 2009-2014
Figure 11: Most active licensing dealmakers 2009-2014 by therapy area
Figure 12: Most active licensing dealmakers 2009-2014 – by stage of development
Figure 13: Bigpharma – top 50 – licensing deals 2009 to 2014
Figure 14: Bigpharma licensing deal frequency - 2009 to 2014
Figure 15: Bigbiotech – top 50 – licensing deals 2009 to 2014
Figure 16: Bigbiotech licensing deal frequency - 2009 to 2014
Figure 17: Licensing deal headline value distribution, US$million – discovery stage
Figure 18: Licensing deal headline value distribution, US$million – preclinical stage
Figure 19: Licensing deal headline value distribution, US$million – phase I stage
Figure 20: Licensing deal headline value distribution, US$million – phase II stage
Figure 21: Licensing deal headline value distribution, US$million – phase III stage
Figure 22: Licensing deal headline value distribution, US$million – regulatory stage
Figure 23: Licensing deal headline value distribution, US$million – marketed stage
Figure 24: Summary median licensing headline value by stage of development, 2009-2014
Figure 25: Licensing deal upfront payment distribution, US$million – discovery stage
Figure 26: Licensing deal upfront payment distribution, US$million – preclinical stage
Figure 27: Licensing deal upfront payment distribution, US$million – phase I stage
Figure 28: Licensing deal upfront payment distribution, US$million – phase II stage
Figure 29: Licensing deal upfront payment distribution, US$million – phase III stage
Figure 30: Licensing deal upfront payment distribution, US$million – regulatory stage
Figure 31: Licensing deal upfront payment distribution, US$million – marketed stage
Figure 32: Summary median licensing upfront payments by stage of development, 2009-2014
Figure 33: Licensing deal milestone distribution, US$million – discovery stage
Figure 34: Licensing deal milestone distribution, US$million – preclinical stage
Figure 35: Licensing deal milestone distribution, US$million – phase I stage
Figure 36: Licensing deal milestone distribution, US$million – phase II stage
Figure 37: Licensing deal milestone distribution, US$million – phase III stage
Figure 38: Licensing deal milestone distribution, US$million – regulatory stage
Figure 39: Licensing deal milestone distribution, US$million – marketed stage
Figure 40: Licensing deals with royalty rates, %
Figure 41: Licensing deal royalty rate distribution, US$million – discovery stage
Figure 42: Licensing deal royalty rate distribution, US$million – preclinical stage
Figure 43: Licensing deal royalty rate distribution, US$million – phase I stage
Figure 44: Licensing deal royalty rate distribution, US$million – phase II stage
Figure 45: Licensing deal royalty rate distribution, US$million – phase III stage
Figure 46: Licensing deal royalty rate distribution, US$million – regulatory stage
Figure 47: Licensing deal royalty rate distribution, US$million – marketed stage
Figure 48: Summary median licensing royalty rate by stage of development, 2009-2014
Figure 49: Online partnering resources
Figure 50: Deal type definitions
$2,995
My Basket
You have no items in your shopping cart.
Need Help?
Unsure which report to purchase or have a query regarding a report, please contact us and we'll be glad to help.
Contact our Report Store Team
Email us or call
+44 (0)1904 435190 Europe
+1 (813) 971.8273 US
- Most Viewed